Inventisbio Co., Ltd

This Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% imp…

This Phase 3 trial tests D-2570, a new daily pill, in 477 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570, an active comparator (BMS-986165), or a placebo. The study measures how well the drug clears skin and improves quality …

This phase 2 trial tests whether the experimental drug D-2570 can help people with active systemic lupus erythematosus (SLE). About 120 adults with moderate-to-severe lupus will be randomly assigned to receive either D-2570 or a placebo. The main goal is to see if D-2570 improves…

This study tests an experimental oral drug called D-2570 in 222 adults with active psoriatic arthritis. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see if D-2570 reduces joint tenderness and swelling by at least 20% compared to placebo.

This phase 3 trial compares a new oral drug, D-0502, against the standard injection fulvestrant for people with ER-positive, HER2-negative advanced or metastatic breast cancer. The study aims to see if D-0502 can delay cancer growth better than fulvestrant. About 640 participants…

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if the drug can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for at lea…